Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Teucrium Corn Fund (CORN) vs Novo Nordisk A/S (NVO) Price & Performance

Teucrium Corn FundTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Teucrium Corn Fund vs Novo Nordisk A/S — how do they compare? Teucrium Corn Fund trades at $17.55, while Novo Nordisk A/S trades at $49.26 (market cap $214.94B). The key difference: Novo Nordisk A/S pays a 3.67% dividend while Teucrium Corn Fund pays none. Which is the better fit depends on your goals.

CORNNVO
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$19.12$71.70
52-Week Low
$16.46$35.29
Market Cap
$214.94B
Enterprise Value
$233.91B
Dividend Yield
3.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Teucrium Corn Fund

CORN stock trades at $17.55 with a slight 0.4% daily gain, showing bullish technical momentum with strong moving average support. The company's financial ratios remain undisclosed in current data, limiting fundamental visibility. Recent partnership news with Hormel Foods for CORN NUTS brand licensing provides potential growth catalyst, while technical indicators suggest continued upward pressure with key resistance at $18.

Outlook remains cautiously optimistic given bullish technical signals and brand expansion opportunities, though limited financial transparency presents valuation challenges. Key risks include commodity price volatility and competitive pressures in the snack food sector. Investors should monitor upcoming earnings for fundamental clarity while technical momentum supports near-term upside potential.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.

Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Teucrium Corn Fund

CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.

Read more on CORN

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO